Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: A post-hoc analysis

Peter J. Goadsby, David William Dodick, James M. Martinez, Margaret B. Ferguson, Tina M. Oakes, Qi Zhang, Vladimir Skljarevski, Sheena K. Aurora

Research output: Contribution to journalArticle

3 Scopus citations


Background and objective: As new migraine prevention treatments are developed, the onset of a preventive effect, how long it is maintained and whether patients initially non-responsive develop clinically meaningful responses with continued treatment can be assessed. Methods: Analyses were conducted post-hoc of a double-blind, placebo-controlled, phase II-a study in patients with episodic migraine receiving galcanezumab 150 mg or placebo biweekly for 12 weeks (Lancet Neurol 13:885, 2014). The number of migraine headache days per week, and onset of efficacy measured as the first week galacanezumab separated from placebo were determined. Patients with ≥50%, ≥75% and 100% reduction in migraine headache days from baseline at months 1, 2 and 3 were calculated and defined as sustained responses. Non-responders (<50% response) at month 1 or 2 who then showed ≥50%, ≥75% and 100% response at later time-points were calculated. Results: Patients were randomised to galcanezumab (n=107) or placebo (n=110). A significant (p=0.018) change of '0.89±0.11 (galcanezumab) vs '0.53±0.11 (placebo) migraine headache days indicated onset at week 1. Forty-seven per cent of galcanezumab and 25% of placebo patients responding at month 1 maintained response through months 2 and 3. Of non-responders at month 1, 27% on galcanezumab and 20% on placebo responded on months 2 and 3, and 50% of galcanezumab non-responders in months 1 and 2 responded on month 3, vs 24% on placebo. Conclusions: The onset of efficacy of galcanezumab is within 1 week in a majority of patients, and patients receiving galcanezumab are twice more likely to maintain responses than placebo patients. Early non-responders may respond by month 2 or month 3. Trial registration number: NCT01625988.

Original languageEnglish (US)
JournalJournal of Neurology, Neurosurgery and Psychiatry
StatePublished - Jan 1 2019



  • calcitonin gene-related peptide
  • CGRP
  • clinical trial
  • galcanezumab
  • LY2951742
  • migraine

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this